Kimia was launched in January 2023 as a spin-out from Carmot Therapeutics and aims to leverage its Chemotype Evolution technology to build a next-generation therapeutics discovery platform. The company is focused on using its ATLAS platform to identify druggable sites and develop novel drugs for treating human diseases. Dr. Haque's expertise in machine learning and AI is expected to enhance Kimia's capabilities in drug discovery and development, positioning the company as a leader in AI/ML-enabled therapeutics.
Key takeaways:
- Kimia Therapeutics appointed Imran S. Haque, Ph.D., as Chief Technology Officer to lead the development of its ATLAS technology platform.
- Dr. Haque brings nearly 20 years of experience in chemistry, biology, and machine learning, previously leading AI and digital sciences at Recursion.
- Kimia's ATLAS platform integrates high-throughput chemistry, machine learning, and genome editing to advance drug discovery, focusing on cancer and immunology.
- Kimia was launched in January 2023 as a spin-out of Carmot Therapeutics, leveraging Chemotype Evolution technology for next-generation therapeutics discovery.